Jennifer Dittman Biography and Net Worth

Jennifer Dittman joined Third Harmonic Bio in November 2022, as Vice President of Regulatory Affairs and was promoted to Chief Operating Officer in 2024. In her expanded role, she is responsible for regulatory affairs, program management, quality, and CMC. Prior to joining Third Harmonic Bio, Jennifer was Vice President of Regulatory Affairs and Medical Writing at Generation Bio, where she was responsible for platform and pipeline regulatory activities. Before Generation Bio, she held roles of increasing responsibility at Vertex Pharmaceuticals, most recently serving as Executive Director, Therapeutic Area Head, in Regulatory Affairs, where she helped set the global regulatory strategy for multiple pipeline products in development, including small molecule and gene therapy/editing programs. Earlier in her career, Ms. Dittman served in roles of increasing responsibility in Regulatory Affairs at bluebird bio and was Adjunct Faculty in the Regulatory Affairs program at Northeastern University.

She holds a M.S. in regulatory affairs for drugs, biologics, and medical devices from Northeastern University.